文献速递前列腺癌

前列腺HistoScanning与经会阴模板穿刺活检对比验证研究

Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-10-02

PICTURE研究为前瞻性配对队列验证试验,纳入330例既往TRUS活检后仍需再活检的男性,其中249例同时接受PHS和经会阴模板前列腺穿刺活检(TTPM,参考标准)。主要评估PHS排除Gleason≥4+3和/或癌核心长度≥6mm临床显著前列腺癌的能力,结果显示PHS敏感性70.3%、阴性预测值41.3%,无法有效用于风险分层。

要点

  • PHS排除临床显著前列腺癌的敏感性70.3%、NPV 41.3%,性能不足。
  • PHS靶向穿刺的靶向敏感性仅13.6%,不能可靠指导活检。
  • PHS不适用于初次前列腺活检后需风险分层的男性。

核心结论

  • PHS在初次前列腺活检后需风险分层的男性中不是有用的检测方法。

研究设计与样本

  • PICTURE为前瞻性配对队列验证试验(NCT01492270),2012年1月11日至2014年1月29日纳入330例既往TRUS活检后诊断不确定的男性,249例同时接受PHS和TTPM活检(参考标准)。

主要发现

  • PHS排除Gleason≥4+3和/或MCCL≥6mm的敏感性70.3%(95%CI 59.8-79.5),NPV 41.3%(95%CI 27.0-56.8),特异性14.7%(95%CI 9.1-22.0),PPV 36.8%(95%CI 29.6-44.4)。
  • 213/220例有PHS可疑区域并接受靶向穿刺,靶向敏感性13.6%(95%CI 7.3-22.6),特异性97.6%(95%CI 93.1-99.5),NPV 61.6%(95%CI 54.5-68.4),PPV 80.0%(95%CI 51.9-95.7)。

关键数值与推荐

  • 目标组织学条件为Gleason≥4+3和/或癌核心长度(MCCL)≥6mm。
  • PHS排除该条件的敏感性70.3%(95%CI 59.8-79.5),NPV 41.3%(95%CI 27.0-56.8)。

临床怎么用

  • 对于初次前列腺活检后仍需再活检决策的男性,不应使用PHS进行风险分层或指导活检。

局限性

  • 330例入组中仅249例同时接受PHS和TTPM活检,存在未配对情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men with negative prostate biopsies or those diagnosed with low-risk or low-volume intermediate-risk prostate cancers often require a second prostate biopsy prior to a treatment decision. Prostate HistoScanning (PHS) is an ultrasound imaging test that might inform prostate biopsy in such men. METHODS: PICTURE was a prospective, paired-cohort validating trial to assess the diagnostic accuracy of imaging in men requiring a further biopsy (clinicaltrials.gov, NCT01492270) (11 January 2012-29 January 2014). We enrolled 330 men who had undergone a prior TRUS biopsy but where diagnostic uncertainty remained. All eligible men underwent PHS and transperineal template prostate mapping (TTPM) biopsy (reference standard). Men were blinded to the imaging results until after undergoing TTPM biopsies. We primarily assessed the ability of PHS to rule out clinically significant prostate (negative predictive value [NPV] and sensitivity) for a target histological condition of Gleason ≥4+3 and/or a cancer core length (MCCL) ≥6 mm. We also assessed the role of visually estimated PHS-targeted biopsies. RESULTS: Of the 330 men enrolled, 249 underwent both PHS and TTPM biopsy. Mean (SD) age was 62 (7) years, median (IQR) PSA 6.8 (4.98-9.50) ng/ml, median (IQR) number of previous biopsies 1 (1-2) and mean (SD) gland size 37 (15.5) ml. One hundred and forty six (59%) had no clinically significant cancer. PHS classified 174 (70%) as suspicious. Sensitivity was 70.3% (95% CI 59.8-79.5) and NPV 41.3% (95% CI 27.0-56.8). Specificity and positive predictive value (PPV) were 14.7% (95% CI 9.1-22.0) and 36.8% (95% CI 29.6-44.4), respectively. In all, 213/220 had PHS suspicious areas targeted with targeting sensitivity 13.6% (95% CI 7.3-22.6), specificity 97.6% (95% CI 93.1-99.5), NPV 61.6% (95% CI 54.5-68.4) and PPV 80.0% (95% CI 51.9-95.7). CONCLUSIONS: PHS is not a useful test in men seeking risk stratification following initial prostate biopsy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Simmons LAM, Kanthabalan A, Arya M, et al. Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning. Prostate Cancer Prostatic Dis. 2018. PMID: 30279583. doi:10.1038/s41391-018-0094-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。